Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SML2057

Sigma-Aldrich

Bevirimat

≥98% (HPLC)

Sinónimos:

(3b)-3-(3-Carboxy-3-methyl-1-oxobutoxy)lup-20(29)-en-28-oic acid, 3-0-(3′-3′-Dimethylsuccinyl)betulinic acid, BVM, MPC-4326, O-(3,3-Dimethylsuccinyl)betulinic acid, PA-457

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C36H56O6
Número de CAS:
174022-42-5
Peso molecular:
584.83
MDL number:
MFCD00954243
UNSPSC Code:
51111800
NACRES:
NA.77

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

SMILES string

CC([C@H]1[C@]2([H])[C@@]3([H])CC[C@@]4([H])[C@](CC[C@]5([H])[C@]4(C)CC[C@H](OC(CC(C)(C(O)=O)C)=O)C5(C)C)(C)[C@]3(C)CC[C@@]2(C(O)=O)CC1)=C

InChI

1S/C36H56O6/c1-21(2)22-12-17-36(30(40)41)19-18-34(8)23(28(22)36)10-11-25-33(7)15-14-26(42-27(37)20-31(3,4)29(38)39)32(5,6)24(33)13-16-35(25,34)9/h22-26,28H,1,10-20H2,2-9H3,(H,38,39)(H,40,41)/t22-,23+,24-,25+,26-,28+,33-,34+,35+,36-/m0/s1

InChI key

YJEJKUQEXFSVCJ-WRFMNRASSA-N

Biochem/physiol Actions

Bevirimat is the first in class HIV maturation inhibitor. It acts by inhibiting the processing of the Gag capsid (CA)/spacer peptide 1 (SP1), which causes accumulation of CA/SP1 (p25) precursor proteins and blocks maturation of the viral core particle.
It also causes defective core condensation and releases the non-infectious virus particles from cells infected with human immunodeficiency virus (HIV). Thus, bevirimat blocks the spread of HIV infection to other cells.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Albert T Nguyen et al.
Retrovirology, 8, 101-101 (2011-12-14)
Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. In contrast to inhibitors that target the active site of the viral protease, bevirimat specifically inhibits a
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.
Martin DE, et al.
Antimicrobial Agents and Chemotherapy, 51(9), 3063-3066 (2007)
Zeyu Lin et al.
PLoS pathogens, 12(11), e1005990-e1005990 (2016-11-29)
HIV-1 maturation inhibitors (MIs) disrupt the final step in the HIV-1 protease-mediated cleavage of the Gag polyprotein between capsid p24 capsid (CA) and spacer peptide 1 (SP1), leading to the production of infectious virus. BMS-955176 is a second generation MI
Patrick F Smith et al.
Antimicrobial agents and chemotherapy, 51(10), 3574-3581 (2007-07-20)
Bevirimat [3-O-(3',3'-dimethylsuccinyl)betulinic acid] is the first in a new class of anti-human immunodeficiency virus (HIV) drugs that inhibit viral maturation by specifically blocking cleavage of the Gag capsid (CA) precursor, CA-SP1, to mature CA protein, resulting in defective core condensation

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico